Evidence map›Paper›PMID 39485484›Full record

ArticleJournal of the American Society of Nephrology : JASN2025

Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD.

Vikas S Sridhar, Ayodele Odutayo, Satish Garg, Thomas Danne, Alessandro Doria, Michael Mauer, Michael J Davies, Phillip Banks, Manon Girard, David Z I Cherney

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the American Society of Nephrology : JASN, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Type 1 diabetes and cardiovascular medicine.Cardiovascular diabetology. Endocrinology reports · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Vikas S SridharToronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0001-7947-1822
Ayodele OdutayoToronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.ORCID 0000-0001-8619-5010
Satish GargBarbara Davis Center for Diabetes, University of Colorado Denver, Aurora, Colorado.ORCID 0000-0003-4796-3288
Thomas DanneDepartment of Diabetes, Endocrinology, and Clinical Research, Children's and Youth Hospital Auf der Bult, Hannover Medical School, Hannover, Germany.ORCID 0000-0002-8424-3944
Alessandro DoriaResearch Division, Department of Medicine, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-3830-4304
Michael MauerDepartments of Pediatrics and Medicine, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0001-7301-9616
Michael J DaviesLexicon Pharmaceuticals, Inc., The Woodlands, Texas.ORCID 0009-0008-4941-0883
Phillip BanksLexicon Pharmaceuticals, Inc., The Woodlands, Texas.
Manon GirardLexicon Pharmaceuticals, Inc., The Woodlands, Texas.
David Z I CherneyToronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.

Funding

SPECIAL ASSAY COREP30DK036836 · NIDDK · JOSLIN DIABETES CENTER · PI JEAN E. SCHAFFER · 1986 to 2026
$50.5M
NIDDK NIH HHS P30 DK036836
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

diabetesdiabetic kidney diseaseSGLT2

Identifiers

PMID39485484
PMCPMC12059092

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.